Conflict of Interest Disclosures: Dr Jonaitis reported grants from National Institutes of Health and tau tracer from Cerveau during the conduct of the study. Dr Langhough reported grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Cody reported grants from NIH during the conduct of the study. Dr Wilson reported grants from University of Wisconsin–Madison during the conduct of the study. Dr Carlsson reported grants from NIH during the conduct of the study. Dr Lleó reported personal fees from Fujirebio-Europe, Roche, Biogen, Lilly, and Nutricia outside the submitted work and having had a patent for markers of synaptopathy in neurodegenerative disease licensed to ADx. Dr Alcolea reported grants from Fondo de Investigaciones Sanitario, Carlos III Health Institute, and Departament de Salut de la Generalitat de Catalunya during the conduct of the study; advisory board services and/or speaker honoraria from Fujirebio-Europe, Roche, Nutricia, Krka Farmacéutica, Grifols, Lilly, Zambon, Esteve, and Neuraxpharm outside the submitted work; and having had a patent for EPI8382175.0 licensed to ADx. Dr Fortea reported grants from Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III, NIH, and Horizon 2020 (European Commission) during the conduct of the study; personal fees from Roche, Novo Nordisk, Esteve, Biogen, Laboratorios Carnot, LMI, AC Immune, Alzheon, Lundbeck, and Lilly outside the submitted work; and having had a patent issued for WO2019175379 A1, “Markers of synaptopathy in neurodegenerative disease,” with royalties paid. Dr Rosa-Neto reported funding from the Weston Brain Institute, Canadian Institutes of Health Research (MOP-11-51-31, FRN, 152985); salary award from the Fonds de Recherche du Québec–Santé and Colin J. Adair Charitable Foundation; serving on the advisory board for Novo Nordisk, Eisai, and Eli Lilly; and serving as a consultant for Eisai and Cerveau Radiopharmaceuticals. Dr Johnson reported grants from NIH and advisory board fees from ALZpath during the conduct of the study, grants from Cerveau Technologies paid to his institution outside of the submitted work, and advisory board fees from Roche Diagnostics and Prothena outside the submitted work. Dr Jeromin reported equity from ALZpath and having had a patent pending for ALZpath. Dr Blennow reported having served as a consultant and at advisory boards for Acumen, ALZpath, BioArctic, Biogen, Eisai, Lilly, Moleac, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; having served at data monitoring committees for Julius Clinical and Novartis; having given lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics; and being a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Dr Zetterberg reported advisory board fees from AbbVie, Acumen, Alector, Alzinova, ALZpath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave Scientific; sponsored lecture fees from Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and being a co-founder and stockholder for Brain Biomarker Solutions in Gothenburg AB outside the submitted work. No other disclosures were reported.
PubMed
